Section Review: Anti-infectives: An update on β-lactamases and β-lactamase inhibitors

References

• ABRAHAM EP, CHAIN E: An enzyme from bacteria ableto destroy penicillin. Nature (1940) 146:837–841.
   Google Scholar
• DATTA N, KONTOMICHALOU P: PenicMinase synthesiscontrolled by infectious R-factors in Enterobacte-riaceae. Nature (1965) 208:239–241.
   PubMed Web of Science ®Google Scholar
• LEVINSON DC, GRIFFITHS GC, PEARSON HE: increasingbacterial resistance to antibiotics. Circulation (1950) 2:668–675.
   PubMedGoogle Scholar
• THORNSBERRY C: Trends in antimicrobial resistanceamong today's bacterial pathogens. Pharrnacotherapy (1995) 15:3S–8S.
   Google Scholar
• HOWARD AJ, HINCE CJ, -WILLIAMS JD: Antibiotic resis-tance in Streptococcus pneumoniae and HaemopbRus influerizae. British Medical Journal (1978) 1:1657–1660.
   PubMed Web of Science ®Google Scholar
• GARAU j: P-Lactamases: Current situation and clinicalImportance. Intensive Care Medicine (1994) 20\(Suppl. 3):S5–S9.
   Google Scholar
• BUSH K: Characterization of P-lactamases. Antimicrobial Agents and Chemotherapy (1989) 33:259–263.
   PubMed Web of Science ®Google Scholar
• BUSH K, JACOBY GA, MEDEIROS AA: A functional classi-fication scheme for 13-lactamases and its correlation with molecular structure. Antimicrobial Agents and Che-motherapy (1995) 39:1211–1233.
   PubMed Web of Science ®Google Scholar
• AMBLER RP: The structure of P-lactamases. Philosophical Transactions of the Royal Society, London (1980) 289:321–331.
   PubMed Web of Science ®Google Scholar
• MATAGNE A, MISSELYN-BAUDUIN A-M, JORIS B, ERPICUM T, GRANIER B, FRERE J-M: The diversity of the catalytic properties of the Class A P-lactamases. Biochemistry Journal (1990) 265:131–146.
   PubMed Web of Science ®Google Scholar
• BENNETT PM, CHOPRA I: Molecular basis of Plactamase Induction in bacteria. Antimicrobial Agents and Chemo-therapy (1993) 37:153–158.
   PubMed Web of Science ®Google Scholar
• KERNODLE DS, MCGRAW PS, STRATTON CW, KAISER AB: Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus tamase variants. Antimicrobial Agents and Chemotherapy (1990) 34:420–425.
   PubMed Web of Science ®Google Scholar
• ZYGMUNT DJ, STRATTON CW, KERNODLE DS: Charac-terisation of four P-lactamases produced by Staphylo-coccus aureus. Antimicrobial Agents and Chemotherapy (1992) 36:440–445.
   PubMed Web of Science ®Google Scholar
• BONFIGLIO G, LIVERMORE DM: P-Lactamase types amongst Staphylococcus aureus isolates in relation to susceptibility to 13-lactamase inhibitor combinations. Journal of Antimicrobial Chemotherapy (1994) 33:465–481.
   PubMed Web of Science ®Google Scholar
• ZSCHECK KK, MURRAY BE: Nucleotide sequence of the P-lactamase gene fromEnterococcusfaecalis 111122 and its similarity to staphylococcal beta-lactamase genes. Antimicrobial Agents and Chemotherapy (1991) 35: 1736-1740.
   Google Scholar
• SOUSA JC, CARNEIRO G, PEIXE ML, QUEIROS ML, REBELOI: Characterization of P-lactarnases encoded by patho-genic strains of Escbericbta coil from Portugal Journal of Antimicrobial Chemotherapy (1991) 27:437–440.
   Google Scholar
• ROY C, TERUEL D, REIG R, HERMIDA M, TEIXELL P-Lactamases and susceptibility phenotypes to P-lactam antibiotics inEscherichia coil strains. Journal of Antimi-crobial Chemotherapy (1992) 29:593–594.
   PubMed Web of Science ®Google Scholar
• WU PJ, SHANNON K, PHILLIPS I: P-Lactamases and sus-ceptibility to 13-lactam antibiotics in Escherichia coll. Journal of Antimicrobial Chemotherapy (1992) 30:868–870.
   PubMed Web of Science ®Google Scholar
• THOMSON CJ, AMYES SG: Molecular epidemiology of the plasmid-encoded TEM-1 P-lactamase in Scotland. Epidemiology and Infection (1993) 110:117–125.
   PubMed Web of Science ®Google Scholar
• REIG R, ROY C, HERMEIDA M, TERUEL D, COIRA A: A survey of Plactamases from 618 isolates of Kiebsiella spp. Journal of Antimicrobial Chemotherapy (1993) 31:21–35.
   PubMedGoogle Scholar
• PAGE JWJ, FARMER TH, ELSON SW: Hyperproduction ofTEM-1 P-lactamase by Escherichia coil strains. Journal of Antimicrobial Chemotherapy (1989) 23:160–161.
   PubMed Web of Science ®Google Scholar
• SHANNON K, WILLIAMS H, KING A, PHILLIPS I: Hyperpro-duction of TEM-1 P-lactamase in clinical isolates of Escherichia colt serotype 013. FEMS Microbiology Letters (1990) 55:319–324.
   PubMedGoogle Scholar
• MARTINEZ JL, VICENTE MF, DELGADO IRIBARREN A, PEREZ DIAZ JC, BAQUERO F: Small plasmids are involved In amoxidllin-clavulanate resistance in Escherichia colt. Antimicrobial Agents and Chemotherapy (1989) 33:283–284.
   PubMedGoogle Scholar
• SHAH PM, STILLE W: Escherichia colt and Klebstella pneumontae strains more susceptible to cefoxitin than to third-generation cephalosporins. Journal of Antimi-crobial Chemotherapy (1983) 11:597–598.
   PubMed Web of Science ®Google Scholar
• SIROT J, LABIA R, THABAUT A: Klebsieffa pneumontae strains more resistant to ceftazidlme than to other third-generation cephalosporins. Journal of Antimicro-bial Chemotherapy (1987) 20:611–612.
   PubMedGoogle Scholar
• JACOBY GA, MEDELROS AE: More extended-spectrum 13-lactamases. Antimicrobial Agents and Chemotherapy (1991) 35: 1697-1704.
   Google Scholar
• BLAZQUEZ J, MOROSINI M-I, NEGRI M-C, GONZALEZ-LEIZA M, BAQUERO F Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM ll-lactamases. Antimicrobial Agents and Chemotherapy (1995) 39:145–149.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN FW, PEAN Y, ROSATO A, GERTNER J, GUT-MANN L AND THE VIGIL'ROC STUDY GROUP: Charac-terisation of ceftriaxone-resistant Enterobacteriaceae: a multicentre study in 26 French hospitals. Journal of Antimicrobial Chemotherapy (1993) 32:595–603.
   PubMed Web of Science ®Google Scholar
• PAYNE DJ, AMYES SGB: Transferable resistance to ex-tended-spectrum ll-lactams: A major threat or a minor Inconvenience? Journal of Antimicrobial Chemotherapy (1991) 27:255–261.
   PubMed Web of Science ®Google Scholar
• SIROT D, SIROT J, LABIA R, MORAND A, COURVALIN P,DARFEUILLE MA, PEROUX R, CLUZEL R: Transferable resistance to third-generation cephalosporins in clini-cal isolates of Klebsiella pneuntoniae: Identification of CTX-1, a novel ll-lactanaase. Journal of Antimicrobial Che-motherapy (1987) 20:323–324.
   PubMed Web of Science ®Google Scholar
• JARLIER V, NICOLAS MH, FOURNIER G, PHILLIPON A: Extended broad-spectrum ll-lactamases conferring transferable resistance to newer ll-lactam agents in Enterobacteriaceae: Hospital prevalence and suscepti-bility patterns. Reviews of Infectious Diseases (1988) 10:867–878.
   PubMedGoogle Scholar
• PODBIELSKI A, SCHONLING J, MELZER B, HAASE G: Dif-ferent promoters of SHV-2 and SHV-2a ll-lactamase lead to diverse levels of cefotaxime resistance in the bacte-rial producers. Journal of General Microbiology (1991) 137: 1667-1675.
   Google Scholar
• THOMSON CJ, AMYES SGB: TRC-1: emergence of a clavu-lank acid-resistant TEM ll-lactamase in a clinical strain. FEMS Microbiology Letters (1992) 70:113–117.
   PubMedGoogle Scholar
• VEDEL G, BELAAOUAJ A, GILLY L, LABIA R, PHILLIPON A, NEVOT P, PAUL G: Clinical isolates of Escberkbia colt producing TR1 ll-lactamases: novel TEM-enzymes con-ferring resistance to ll-lactamase inhibitors. Journal of Antimicrobial Chemotherapy (1992) 30:449–462.
   PubMed Web of Science ®Google Scholar
• BLAZQUEZ J, BAQUERO M-R, CANTON R, ALOS I, BAQUERO F: Characterization of a new TEM-type ll-lac-tamase resistant to clavulanate, sulbactam, and tazobac-tam in a clinical isolate ofEscherichia coll. Antimicrobial Agents and Chemotherapy (1993) 37:2059–2063.
   PubMed Web of Science ®Google Scholar
• HENQUELL C, CHANAL C, SIROT D, LABIA R, SIROP 3: Molecular characterization of nine different types of mutants among 107 inhibitor-resistant 13-lactamases from clinical isolates of Eseberkbia col. Antimicrobial Agents and Chemotherapy (1995) 39:427–430.
   PubMed Web of Science ®Google Scholar
• HENQUELL C, SIROT D, CHANAL C, DE CHAMPS C, CHA-TRON P, LAFEUILLE B, TEX1ER P, SIROT J, CLUZEL R: Frequency of inhibitor-resistant TEM ll-lactamases in Eschericbia coil isolates from urinary-tract infections In France. Journal of Antimicrobial Chemotherapy (1994) 34:707–714.
   PubMed Web of Science ®Google Scholar
• REID AJ, SIMPSON IN, HARPER PB, AMYES SGB: The differential expression of genes for the P5E-4 ll-lac-tamase in Pseudomonas aerugtnosa and the Entero-bacteriaceae. Journal of Antimicrobial Chemotherapy (1988) 21:525–533.
   PubMed Web of Science ®Google Scholar
• HUOVINEN P, JACOBY GA: Sequence of the PSE-1 ll-lac-tamase gene. Antimicrobial Agents and Chemotherapy (1990 35:2428–2430.
   Web of Science ®Google Scholar
• BOISSINOT M, LEVESQUE RC: Nudeotide sequence of the PSE-4 carbenicillinase gene and correlations with the Staphylococcus aureus PC1 ll-lactamase crystal struc-ture. Journal of Biological Chemistry (1990) 265:1225–1230.
   PubMed Web of Science ®Google Scholar
• LACHAPELLE J, DUFRESNE J, LEVESQUE RC: Charac-terisation of the bla sub(C4RB-3) gene encoding the carbenici11inase-3 ll-lactamase ofPseudomonas aerugi-nosa. Gene (1991) 102:7–12.
   PubMed Web of Science ®Google Scholar
• LEDENT P, RAQUET X, JORIS B, VAN-BEEUMEN J, FRERE J-M: A comparative study of Class D ll-lactamases. Bio-chemistry Journal (1993) 292:555–562.
   PubMed Web of Science ®Google Scholar
• LIU PYF, GUR D, HALL LMC, LIVERMORE DM: Survey of the prevalence of ll-lactamases amongst 1000 Gram-negative bacilli isolated consecutively at the Royal Lon-don Hospital. Journal of Antimicrobial Chemotherapy (1992) 30:429–447.
   PubMed Web of Science ®Google Scholar
• NORDMANN P, MAR101 it S, NAAS T, LABIA R, NICOLAS MU: Biochemical properties of a carbapenem-hydrolyz-ing ll-lactamase fromEnterobacter cloacae and cloning of the gene into Eschmichia col. Antimicrobial Agents and Chemotherapy (1993) 37:939–946.
   PubMed Web of Science ®Google Scholar
• NAAS T, NORDMANN P: Analysis of a carbapenem-hy-drolyzing class A ll-lactarnase from Enterobacter cloa-cae and of its LysR-type regulatory protein. Proceedings of the National AcariPmy of Sciences of the United States of America (1994) 91:7693–7697.
   PubMed Web of Science ®Google Scholar
• NAAS T, VANDEL L, SOUGAKOFF W, LIVERMORE DM, NORDMANN P: Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A ll-lactamase, Sme-1, from Serratia marcescens. Antimicrobial Agents and Chemotherapy (1994) 38:1262–1270.
   PubMed Web of Science ®Google Scholar
• PAYNE DJ: Metallo-ll-lactamases - a new therapeutic challenge. Journal of Medical Microbiology (1993) 39:93–99.
   PubMed Web of Science ®Google Scholar
• BANDOH K, UENO K, WATANABE K, KATO N: Suscepti-bility patterns and resistance to imipenem in the Bac-teroidesfragilis group species in Japan: a 4-year study. Clinical Infectious Diseases (1993) 16\(Suppl. 4):S382–386.
   Google Scholar
• BURNAT C, MALKIN JE, DUBLANCHET A, BREUIL J: The antibiotic sensitivity of the Bacteroides fragtlls group In France - the 1989 survey. Medecine et Maladies Infec-tieuses (1990) 20:121–123.
   Web of Science ®Google Scholar
• PODGLAJEN I, BREUIL J, BORDON F, GUTMANN L, COL-LATZ E: A silent carbapenemase gene in strains of Bacteroides fragilis can be expressed after a one-step mutation. FEMS Microbiology Letters (1992) 70:21–30.
   PubMedGoogle Scholar
• BAXTER IA, LAMBERT PA: Isolation and partial purifica-tion of a carbapenem-hydrolysing metallo-13-lactatnase from Pseudomonas cepacia. FEMS Microbiology letters (1994) 122:251–256.
   PubMed Web of Science ®Google Scholar
• WALSH TR, HALL L, ASSINDER SJ, NICHOLS WW, CART-WRIGHT SJ, MACGOWAN AP, BENNETT PM: Sequence analysis of the Li metallo-13-lactamase from Xantho-monas maltophilia. Biochimica et Biophysica Acta (1994) 1218:199–201.
   PubMed Web of Science ®Google Scholar
• PATON R, MILES RS, AMYES SG: Biochemical propertiesof inducible f3-lactamases produced fromXanthomonas mattophilia. Antimicrobial Agents and Chemotherapy (1994) 38:2143–2149.
   PubMed Web of Science ®Google Scholar
• OSANO E, ARAICAWA Y, WACHAROTAYANKUN R, OHTA M, HORII T, ITO H, YOSHIMURA F, KATO N: Molecular characterisation of an enterobacterial metallo-P-lac-tamase found in a clinical isolate of Serrafia marces-cens that shows imipenem resistance. Antimicrobial Agents and Chemotherapy (1994) 38:71–78.
   PubMed Web of Science ®Google Scholar
• SEGATORE B, MASSIDDA 0, SATTA G, SETACCI D, AMI-COSANTE G: High specificity of cbpA -encoded metallo-O-lactamase from Aeromonas hydrophila AE036 for carbapenems and its contribution to P-lactam resis-tance. Antimicrobial Agents and Chemotherapy (1993) 37:1324–1328.
   PubMed Web of Science ®Google Scholar
• ROSSOLINI GM, ZANCHI A, CHIESURIN A, AMICOSANTEG, SATTA G, GUGLIELMETTI P: Distribution of cpbA or related carbapenemase-encoding genes and produc-tion of carbapenemase activity in members of the genus Aeromonas . Antimicrobial Agents and Chemotherapy (1995) 39:346–349.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI H, NUKAGA M, SAWAI T: Klebsiella pneu-moniae RDK4 metallo-O-lactarnase. EMBL Database (1994) Accession Number D29636.
   Google Scholar
• CULLMAN W, DICK W: Induction potency of various 13-lactam derivatives in Gram-negative rods. Chemother-apy(1989) 35:43–53.
   PubMed Web of Science ®Google Scholar
• PHILLIPS I, SHANNON K: Importance of 13-lactamase Induction. European Journal of Clinical Microbiology and Infectious Diseases (1993) 12\(Suppl. 1):S19–S26.
   Google Scholar
• LINDBERG F, NORMARK S: Contribution of chromoso-mal fl-lactamases to Plactam resistance in Enterobacte-ria. Reviews of Infectious Diseases (1986) 8\(Suppl. 3):5292–S304.
   Google Scholar
• KORFMANN G, WIEDEMANN B: Genetic control of 3-lac-tamase production in Enterobacter cloacae. Reviews of Infectious Diseases (1988) 10:793–799.
   PubMedGoogle Scholar
• SAUNDERS CC, SAUNDERS WE: Emergence of resistance during therapy with the newer li-lactam antibiotics: Role of inducible Plactamases and implications for the future. Reviews of Infectious Diseases (1983) 5:639–648.
   PubMedGoogle Scholar
• SATAKE S, YONEYAMA H, NAKAE T: Role of OmpD2 and chromosoma113-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy (1991) 28:199–207.
   PubMed Web of Science ®Google Scholar
• FUNG-TOMC JC, HUCZCO E, BANVILLE J, MENARD M, KOLEC B, GRADELSKI E, KESSLER RE, BONNER DP: Struc-ture-activity relationships of carbapenems that deter-mine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa. Journal of Antimicro-bial Chemotherapy (1995) 39:394–399.
   PubMed Web of Science ®Google Scholar
• CORNAGLIA G, RUSSELL K, SATTA G, FONTANA R: Rela-tive importance of outer membrane permeability and group 1 13-lactamase as determinants of meropenem and itnipenem activities against Enterobacter cloacae. Antimicrobial Agents and Chemotherapy (1995) 39:350–355.
   PubMed Web of Science ®Google Scholar
• PAPANICOLALT GA, MEDEIROS AA, JACOBY GA: Novelplasmid-mediated13-lactamase (MIR-1) conferring resis-tance to oxyimino- and alpha-methoxy 13-lactams in clinical isolates of Klebsiellapneumonuae. Antimicrobial Agents and Chemotherapy (1990) 34:2200–2209.
   PubMedGoogle Scholar
• PAYNE DJ, WOODFORD N, AMYES SG: Characterizationof the plasmid mediated P-lactamase BIL-1. Journal of Antimicrobial Chemotherapy (1992) 30:119–127.
   PubMed Web of Science ®Google Scholar
• AMYES SG: Plasmid-mediated 13-lactamases: Relative clinical importance. In: 13-Lactamases: Current Perspec-tives. Proceedings of a Satellite Symposium at the Third European Congress of Clinical Microbiology. The Hague, Netherlands, 12th May, 1987. Livermore DM (Ed.) (1987):31–48.
   Google Scholar
• ZHU YE, CURRAN IHA, JORIS B, GHUYSEN J-M, LAMPENJO: Identification of Mall, the signal transducer for Plactamase production in Bacillus licheniformis, as a penicillin-binding protein with strong homology to the OXA-2 13-lactamase (class D) of Sabnonella typhi-murium. Journal of Bacteriology (1990) 172:1137–1141.
   PubMed Web of Science ®Google Scholar
• BENZ R: Uptake of solutes through bacterial outer mem-branes. In: Bacterial Cell Wall. Ghuysen J-M, Hackenbeck R (Eds.). Elsevier Science By, Amsterdam (1994).
   Google Scholar
• NIKAIDO H, NORMARK S: Sensitivity of Escbericbia coilto various P-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic 0-lactamases: A quantitative predictive treatment Molecular Microbiology (1987) 1:29–36.
   Google Scholar
• MASUDA N, SAKAGAWA E, OHYA S: Outer membraneproteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Che-motherapy (1995) 39:645–649.
   PubMed Web of Science ®Google Scholar
• XIAN-ZHI L, MA D, LIVERMORE DM, NIKA1D0 H: Role ofefflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to 3-lactam resistance. Antimicrobial Agents and Chemother-apy (1994) 38: 1742-1752.
   Google Scholar
• DAOUST DR, ONISHI HE, WALLICK H, HENDLIN D, STA-PLEY EO: C,ephamycins, a new family of 13-lactam anti-biotics: antibacterial activity and resistance to 13-lactamase degradation. Antimicrobial Agents and Che-motherapy (1973) 3:254–261.
   PubMed Web of Science ®Google Scholar
• CLTNHA BA: Third-generation cephalosporins: a review.Clinical Therapy (1992) 14:616–652.
   PubMed Web of Science ®Google Scholar
• SEGRETI J, TRENHOLME GM: 13-Lactamase inhibitors andnew cephalosporins. Current Opinion in Infectious Dis-eases (1993) 6:731–736.
   Web of Science ®Google Scholar
• CHOPRA I: Progress in carbapenem research. Expert Opinion on Investigational Drugs (1995) 4:127–130.
   Google Scholar
• COLE M: Inhibition of 13-lactamases.13-Lactamases.Hamilton-Miller JMT, Smith JT (Eds.). Academic Press, Lon-don (1979).
   Google Scholar
• READING C, COLE M: Clavuianic add: a 13-lactamase-in-hiting 13-lactain from Streptonsyces clavuligerus. An-timicrobial Agents and Chemotherapy (1977) 11:852–857.
   PubMed Web of Science ®Google Scholar
• HUNTER PA, COLEMAN K, FISHER J, TAYLOR D: In vitro synergistic properties of clavulanic acid, with am-pielilIn arnoxycillin and ticarcillin. Journal of Antimicro-bial Chemotherapy (1980) 6:455–470.
   PubMed Web of Science ®Google Scholar
• RETSEMA JA, SCHELKLY WU, GIRARD AE, ENGLISH AR: (3-Lactamase Inhibitor CP-45, 899 (Sulbactam) mode of action against a Type III13-lactamase and synergy effects with cephalosporins. Drugs in Experimental and Clinical Research (1981) 7:255–261.
   Google Scholar
• GUTMANN L, KITZIS M, YAMABE S, AGAR JF: Comparativeevaluation of a new 13-lactamase inhibitor, YTR 830, combined with different 13-lactam antibiotics against bacteria harboring known 13-lactainases. Antimicrobial Agents and Chemotherapy (1986) 29:955–957.
   PubMed Web of Science ®Google Scholar
• JACOBS MR, ARONOFF SC, JOHENNING S, SCHLAES DM,YAMABE S: Comparative activities of the 13-lactamase Inhibitors I'TR 830, clavulanate, and sulbactam com-bined with ampicillin and broad-spectrum penidllins against defined 13-lactamase-producing aerobic Gram-negative bacilli Antimicrobial Agents and Chemotherapy (1986) 29:980–985.
   Google Scholar
• VON DAEHNE W: 613-Halopenicllianic adds, a group of13-lactamase inhibitors. Journal of Antibiotics (1980) 33:451–452.
   PubMed Web of Science ®Google Scholar
• WISE R, O'SULLIVAN N, JOHNSON J, ANDREWS JM: Phar-macokinetics and tissue penetration of ampiciWn and brobactam following oral administration of 2085P. An-timicrobial Agents and Chemotherapy (1992) 36:1002–1004.
   PubMed Web of Science ®Google Scholar
• MELCHIOR NH, KEIDING J: In vitro evaluation of am-picillin/brobactam and comparison with other 13-lac-tam antibiotics. Journal of Antimicrobial Chemotherapy (1991) 27:29–40.
   PubMed Web of Science ®Google Scholar
• BAUERNFEIND A: Perspectives of 13-lactamase inhibitors In therapy of infections caused by Escbericbia colt or Klebsiella spp. with plasmidic resistance to third gen-eration cephalosporins. Infection (1994) 18:48–52.
   Google Scholar
• COULTON S, FRANCOIS I: I3-Lactamases: targets for drug design. Progress in Medicinal Chemistry (1994) 31:297–349.
   PubMedGoogle Scholar
• DORAN JL, LESKIW BK, AlPPERSBACH S, JENSEN SE: Iso-lation and characterization of a 13-lactamase-inhibitory protein from Streptomyces clavuligerus and cloning and analysis of the corresponding gene. Journal of Bacteriology (1990) 172:4909–4918.
   PubMed Web of Science ®Google Scholar
• STRYNADKA NCJ, JENSEN SE, JOHNS K, BLANCHARD H,PAGE M, MATAGNE A, FRERE J-M, JAMES MNG: Structural and kinetic characterization of a 13-lactamase inhibitor protein. Nature (1994) 368:657–660.
   PubMed Web of Science ®Google Scholar
• ZIEGLER CB, YANG Y, FABIO P, STEINBERG DA, WEISS W, WILDEY MJ, BUSH K: Novel isoxazolinylpenicillanate sulfones as inhibitors of Group 1,2 and 3 fl-lactamases. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando (1994). Abstract C54.
   Google Scholar
• RICHTER H, HUBSCHWERLEN C, KANIA M, KOHL I, PAGE MGP, SPECKLIN J-L, THEN R: 2-13-alkertyl penam sulfones: a new class of 13-lactamase inhibitors. Synthesis and structure-activity relationships. 34th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy, Orlando, 1994. Abstract F147.
   Google Scholar
• RICHTER H, HUBSCHWERLEN C, KANIA M, LABHARDT A,PAGE MGP, 'WINKLER F: Spectrum of action and mecha-nism of reaction of RO 48–1220. 34th lnterscience Confer-ence on Antimicrobial Agents and Chemotherapy, Orlando, 1994. Abstract F149.
   Google Scholar
• GOLDSTEIN FW, KITZIS MD, GUTMANN L, ACAR JF: Invitro activity of RO 48–1220, a new very potent 13-lac-tamase inhibitor. 34th Interscience Conference on Antimi-crobial Agents and Chemotherapy, Orlando, 1994. Abstract F151.
   Google Scholar
• BASKER MJ, OSBORNE NF: 6-(Substituted methylene) penems, potent broad spectrum inhibitors of bacterial 11-lactamase. L Racemic 6-ethylidenepenems. Journal of Antibiotics (1990) 43:70–75.
   Google Scholar
• BROOM NJP, COLEMAN K, HUNTER PA, OSBORNE NF: 6-(Substituted methylene)penems, potent broad spec-trum inhibitors of bacterial 13-lactamase. II. Raoemic furyl and thineyl derivatives . Journal of Antibiotics (1990) 43:76–82.
   PubMedGoogle Scholar
• BENNETT I, BROOM NJP, BRUTON G, CALVERT S, CLARICEBP, COLEMAN K, EDMONDSON R, EDWARDS P, JONES D, OSBORNE NF, WALKER G: 6-(Substituted methylene) penems, potent broad spectrum inhibitors of bacterial 13-lactamase. M. Structure-activity relationships of the flve-membered heterocyclic derivatives. Journal ofAnti-biotics. (1990) 44:331–337.
   Google Scholar
• BENNETT I, BROOM NJP, COLEMAN K, COULTON S, ED-WARDS PD, FRANCOISE I, GRIFFIN DRJ, OSBORNE NF, WOODALL PM: 6-(Substituted methylene)penems, po-tent broad spectrum inhibitors of bacterialf3-lactarnase. IV. Kidney stability, serum binding and additional bio-logical evaluation of racemic derivatives. Journal of Antibiotics. (1991) 44:383–343.
   Google Scholar
• BENNETT I, BROOKS G, BROOM NJP, CALVERT SH, COLE-MAN K, FRANCOIS I: 6-(substituted methylene)penems, potent broad spectrum inhibitors of bacterial f3-lac-tamase. V. Chiral 1,2,3-triazoly1 derivatives. Journal of Antibiotics (1991) 44:969–978.
   Google Scholar
• COLEMAN K, GRIFFIN DRJ, PAGE JWP, UPSHON PA: In vitro evaluation of BRL 42715, a novel f3-lactamase Inhibitor. Antimicrobial Agents and Chemotherapy (1989) 33:1580–1587.
   PubMed Web of Science ®Google Scholar
• FARMER TH, PAGE JWJ, PAYNE DJ, KNOWLES DJC: Kinetic and physical studies of f3-lactamase inhibition by a novel penem, BRL 42715. Biochemistry Journal (1994) 303:825–830.
   PubMed Web of Science ®Google Scholar
• BULYCHEV A, MASSOVA I, LERNER SA, MOBASHERY S: Penem BRL 42715: an effective inactivator for f3-lac-tamases. Journal of the American Chemical Society (1995). In press.
   Google Scholar
• QADRI SM, UENO Y, BURDETTE M, KROSCHINSICY R, ALMODOVAR E: Evaluation of BRL 42715, a f3-lactamase-inhibiting penem. Chemotherapy (1991) 37:398–404.
   PubMed Web of Science ®Google Scholar
• PIDDOCK U, JIN YF, TURNER HL: Activity of 1313-lactam agents combined with BRL 42715 against 13-lactamase producing Gram-negative bacteria compared to combi-nations with clavulanic acid, tazobacta:m and sulbac-tam. Journal of Antimicrobial Chemotherapy (1993) 31:89–103.
   PubMed Web of Science ®Google Scholar
• MURATANI T, YOKOTA E, NAKANE T, INOUE E, MIT-SUHASHI S: In vitro evaluation of the four 13-lactamase Inhibitors: BRL 42715, clavulanic add, sulbactatn and tazobactam. Journal of Antimicrobial Chemotherapy (1993) 32:421–429.
   PubMed Web of Science ®Google Scholar
• COLEMAN K, GRIFFIN DRJ: The activity of the 13-lactamase Inhibitor BRL 42715 against high-level constitutive fl-lactamase producing strains of Ettterobacter. Journal of Chemotherapy (1991) Supplement N4:147–148.
   Google Scholar
• COLEMAN K, FRANCOIS I, GRIFFIN DRJ, UPSHON P: Com-parative in vitro and in vivo activities of the 0-1actarnase Inhibitors BRL 42715, clavulanic add, tazobactam and sulbactarn combined with amoxydllin. Journal of Che-motherapy (1991) Supplement N4:143–145.
   Google Scholar
• WOODNUTT G, BERRY V, MIZEN L: Simulation of human pharmacokinetics of cefazolin, piperacillin and BRL 42715 in rats and efficacy against experimental in-traperitoneal infections. Antimicrobial Agents and Che-motherapy (1992) 36:1427–1431.
   PubMed Web of Science ®Google Scholar
• COLEMAN K, GRIFFIN DRG, UPSHON PA: Pharmacoki-netic studies and renal dehydropeptidase stability of the new 13-lactamase inhibitor BRL 42715 in animals. Antimicrobial Agents and Chemotherapy (1991) 35: 1748-1752.
   Google Scholar
• PRINCE WT, THOW JC, DAVIES BE, SUTHERLAND R, HOR-TON R: Effect of BRL 42715 on the pharmacokinetics of piperadllin following intravenous administration. Pro-gram Abstract. 30th Interscience Conference on Antimicro-bial Agents and Chemotherapy, 1990. Abstract 823.
   Google Scholar
• FRYDRYCH C, ETAL.: (1995). In press.
   Google Scholar
• FARMER TH, BRYANT DK, READING C, TOLSON DA: The kinetics of P-lactamase inhibition by the penem, SB 206999. Poster presented at the 6th13-Lactamase Workshop. Holy Island, UK. 9-13th April, 1995.
   Google Scholar
• SUTHERLAND it: 13-lactam/13-lactamase inhibitor combi-nations: development, antibacterial activity and clinical applications. Infection (1995) 23(4):1–10.
   PubMedGoogle Scholar
• FRIEDEL HA, CAMPOLI-RICHARDS DM, GOA la: Suliami-cillin. A review of its antibacterial activity, phannacok-inetic properties and therapeutic use. Drugs (1989) 37:491–522.
   Google Scholar
• DIAS MBS, JACOBUS NV, TALLY FP: In vitro activity of cefoperazone-sulbactam against Bacteroides species. Journal of Antimicrobial Chemotherapy (1986) 18:467–471.
   PubMed Web of Science ®Google Scholar
• NEU HC, NIU WW, CHIN NX: Tazobactam prevention of emergence of resistance. Diagnostic Microbiology and Infectious Disease (1989) 12:477–480.
   PubMed Web of Science ®Google Scholar
• CARSENTI-ETESSE H, DURANT J, DE SALVADOR F, BEN-SOUSSAN M, BENSOUSSAN F, PRADIER C, BERNARD E, MONDAIN V, THABAUT A, DELLAMONICA P: Possible prevention of in vitro selection of resistant Streptococ-cus pneumoniae by P-lactamase inhibitors. European Journal of Clinical Microbiology and Infectious Diseases (1994) 13:1058–1062.
   PubMed Web of Science ®Google Scholar
• NEU HC, WILSON APR, GRUNEBERG RN: Amoxycillin/cla-vulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. Journal of Chemotherapy (1993) 5:67–93.
   PubMed Web of Science ®Google Scholar
• ROLINSON GN: A review of the microbiology of amoxy-cillin/clavulanic acid over the 15 year period 1978-1993. Journal of Chemotherapy (1994) 6:283–318.
   PubMed Web of Science ®Google Scholar
• BUSH K, MACALINTAL C, RASMUSSEN BA, LEE VJ, YANG Y: Kinetic interactions of tazobactam with13-lactamases from all major structural classes. Antimicrobial Agents and Chemotherapy (1993) 37:851–858.
   PubMed Web of Science ®Google Scholar